Genetic polymorphisms in emerging cardiovascular risk factors and response to statin therapy

Related Experiment Videos

Kimberly A Dornbrook-Lavender1, John A Pieper

  • 1Department of Pharmacotherapy, University of North Carolina at Chapel Hill School of Pharmacy, Chapel Hill, NC 27599-7360, USA. kadlav@unc.edu

Cardiovascular Drugs and Therapy
|July 5, 2003
PubMed

Insights

Statin therapy benefits coronary heart disease (CHD) patients, particularly those with specific gene variants. Genotyping may personalize statin treatment for improved cardiovascular event reduction.

Area of Science:

  • Cardiology
  • Pharmacogenomics
  • Genetics

Background:

  • Current coronary heart disease (CHD) prevention focuses on traditional risk factors like hypertension, smoking, and cholesterol, emphasizing low-density lipoprotein cholesterol (LDL-C) reduction.
  • Hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) reduce cardiovascular events, but their efficacy varies, suggesting additional mechanisms beyond LDL-C lowering.

Purpose of the Study:

  • To investigate whether genetic variations influence patient response to statin therapy for CHD prevention.
  • To explore the potential of pharmacogenomics in optimizing statin treatment strategies.

Main Methods:

  • Retrospective analysis of statin trial data.
  • Evaluation of associations between polymorphic candidate genes and clinical/metabolic response to statins.
  • Comparison of statin efficacy in patients with variant versus wild-type genotypes.

Main Results:

  • Statin therapy improves lipid profiles in all patients.
  • Individuals with high-risk variant genotypes showed preferential benefits from statin therapy compared to wild-type genotypes.
  • Specific genes analyzed include apolipoprotein E, stromelysin-1, beta-fibrinogen, cholesteryl ester transfer protein, lipoprotein lipase, hepatic lipase, and platelet glycoprotein III.

Conclusions:

  • Genetic factors may predict individual response to statin therapy.
  • Determining patient genotype could personalize statin treatment for enhanced cardiovascular risk reduction.
  • Further prospective studies in genotyped populations are needed to validate these findings.

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...